Table 1 Patient characteristics
Morphine group (n = 45) | Placebo group (n = 45) | |
|---|---|---|
Patient characteristics | ||
Age, ya | 59.9 ± 13.2 | 56.5 ± 10.6 |
Male/female, n (%) | 36 (80.0)/9 (20.0) | 37 (82.2)/8 (17.8) |
Diabetes mellitus, n (%) | 8 (17.8) | 5 (11.1) |
Hypercholesterolemia, n (%) | 14 (31.1) | 13 (28.9) |
Smokers (current or former), n (%) | 33 (73.3) | 31 (68.8) |
Hypertension, n (%) | 20 (44.4) | 16 (35.6) |
Body mass index, kg/m2 a | 27.0 ± 4.1 | 26.0 ± 2.9 |
Medical history, n (%) | ||
History of coronary artery disease | 4 (8.9) | 4 (8.9) |
History of heart failure | 0 (0.0) | 0 (0.0) |
Clinical characteristics | ||
Symptom-to-balloon time, mina | 189 ± 87 | 193 ± 108 |
Killip class > 1, n (%) | 1 (2.2) | 1 (2.2) |
Sustained ventricular arrhythmia before admission, n (%) | 0 (0.0) | 2 (4.4) |
Location of the culprit lesion, n (%) | ||
Left anterior descending artery | 23 (51.1) | 20 (44.4) |
Circumflex coronary artery | 4 (8.9) | 8 (17.8) |
Right coronary artery | 18 (40.0) | 17 (37.8) |
Rentrop score, n (%) | ||
0 | 28 (62.2) | 29 (64.5) |
1 | 10 (22.2) | 10 (22.2) |
2–3 | 7 (15.6) | 6 (13.3) |
Number of diseased vessels, n (%) | ||
1 | 34 (75.6) | 36 (80.0) |
≥ 2 | 11 (24.4) | 9 (20.0) |
Concomitant therapy, n (%) | ||
Aspirin | 45 (100.0) | 44 (97.8) |
P2Y12 receptor blockers | 44 (97.8) | 44 (97.8) |
GPIIb-IIIa receptor inhibitors/bilavirudin | 22(48.9)/20(44.4) | 26(57.7)/16(35.6) |
Intravenous morphine injection | 11 (24.4) | 11 (24.4) |